busulfan (BUSULFEX, MYLERAN)

FDA Approval of a CRISPR/Cas9 Gene Therapy To Treat Sickle Cell Disease
March 2024
In 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for the treatment of sickle cell disease. One of these treatments is the first FDA-approved treatment using CRISPR/Cas9 gene-editing technology. Although cell-based gene therapies for sickle cell disease are promising, they are new, and their long-term effectiveness and safety are not known.

Drug Mix-Ups
June 2011
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.